肿瘤科指南

订阅

MedSci主页 / 所有栏目 / 肿瘤科指南

非小细胞肺癌PD-L1免疫组织化学检测规范中国专家共识

2020-09-25 中国抗癌协会肿瘤病理专业委员会 中国肺癌杂志.2020.23(9):733-740.

非小细胞肺癌

为更好地指导临床检测，中国抗癌协会肿瘤病理专业委员会肺癌学组召集国内部分相关病理专家及临床专家，就PD-L1免疫组化检测的适应证、检测评估复杂性、多样性及临床检测应用注意事项等，参考国内外相关指南及目

中文标题：

非小细胞肺癌PD-L1免疫组织化学检测规范中国专家共识

发布机构：

中国抗癌协会肿瘤病理专业委员会

发布日期：

2020-09-25

简要介绍：

为更好地指导临床检测，中国抗癌协会肿瘤病理专业委员会肺癌学组召集国内部分相关病理专家及临床专家，就PD-L1免疫组化检测的适应证、检测评估复杂性、多样性及临床检测应用注意事项等，参考国内外相关指南及目前中国临床使用和研究现状，讨论并制定本共识供国内同行参考，以期进一步规范和指导肺癌免疫治疗中PD-L1免疫组化检测的临床实践和应用。

相关资料下载：
[AttachmentFileName(sort=1, fileName=非小细胞肺癌PD_L1免疫组织化学检测规范中国专家共识_.pdf)] GetToolGuiderByIdResponse(projectId=1, id=38cb61c0019900a3, title=非小细胞肺癌PD-L1免疫组织化学检测规范中国专家共识, enTitle=, guiderFrom=中国肺癌杂志.2020.23(9):733-740., authorId=0, author=, summary=为更好地指导临床检测，中国抗癌协会肿瘤病理专业委员会肺癌学组召集国内部分相关病理专家及临床专家，就PD-L1免疫组化检测的适应证、检测评估复杂性、多样性及临床检测应用注意事项等，参考国内外相关指南及目, cover=https://img.medsci.cn/20201014/1602608794913_2020535.jpg, journalId=0, articlesId=null, associationId=872, associationName=中国抗癌协会肿瘤病理专业委员会, associationIntro=null, copyright=0, guiderPublishedTime=Fri Sep 25 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>为更好地指导临床检测，中国抗癌协会肿瘤病理专业委员会肺癌学组召集国内部分相关病理专家及临床专家，就PD-L1免疫组化检测的适应证、检测评估复杂性、多样性及临床检测应用注意事项等，参考国内外相关指南及目前中国临床使用和研究现状，讨论并制定本共识供国内同行参考，以期进一步规范和指导肺癌免疫治疗中PD-L1免疫组化检测的临床实践和应用。</p> </div> </div> </div>, tagList=[TagDto(tagId=276, tagName=非小细胞肺癌)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=12, categoryName=呼吸, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=20620, categoryName=肿瘤医学网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=276, guiderKeyword=非小细胞肺癌, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=4044, appHits=264, showAppHits=0, pcHits=992, showPcHits=3778, likes=3, shares=19, comments=24, approvalStatus=1, publishedTime=Wed Oct 14 01:20:55 CST 2020, publishedTimeString=2020-09-25, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Wed Oct 14 01:06:43 CST 2020, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 19:55:33 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=非小细胞肺癌PD_L1免疫组织化学检测规范中国专家共识_.pdf)])
非小细胞肺癌PD_L1免疫组织化学检测规范中国专家共识_.pdf
下载请点击：
评论区 (17)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1208587, encodeId=cfc3120858ea2, content=非常好的资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=00ec8098175, createdName=ms3000000771933475, createdTime=Mon Apr 04 18:50:43 CST 2022, time=2022-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082408, encodeId=48bb108240836, content=学习好资料！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Tue Dec 21 08:51:55 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=995605, encodeId=fa51995605c5, content=也想看看，学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d25474509, createdName=ms1000001533276611, createdTime=Sat Jul 03 08:03:58 CST 2021, time=2021-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976756, encodeId=31999e675695, content=很想看看！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c03d1531849, createdName=429890922, createdTime=Fri Jun 25 10:52:31 CST 2021, time=2021-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974390, encodeId=0dae9e439003, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72da5342867, createdName=ms3000001513748709, createdTime=Thu Jun 17 14:20:00 CST 2021, time=2021-06-17, status=1, ipAttribution=)]
    2022-04-04 ms3000000771933475

    非常好的资料

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1208587, encodeId=cfc3120858ea2, content=非常好的资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=00ec8098175, createdName=ms3000000771933475, createdTime=Mon Apr 04 18:50:43 CST 2022, time=2022-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082408, encodeId=48bb108240836, content=学习好资料！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Tue Dec 21 08:51:55 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=995605, encodeId=fa51995605c5, content=也想看看，学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d25474509, createdName=ms1000001533276611, createdTime=Sat Jul 03 08:03:58 CST 2021, time=2021-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976756, encodeId=31999e675695, content=很想看看！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c03d1531849, createdName=429890922, createdTime=Fri Jun 25 10:52:31 CST 2021, time=2021-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974390, encodeId=0dae9e439003, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72da5342867, createdName=ms3000001513748709, createdTime=Thu Jun 17 14:20:00 CST 2021, time=2021-06-17, status=1, ipAttribution=)]
    2021-12-21 龙珠

    学习好资料！

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1208587, encodeId=cfc3120858ea2, content=非常好的资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=00ec8098175, createdName=ms3000000771933475, createdTime=Mon Apr 04 18:50:43 CST 2022, time=2022-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082408, encodeId=48bb108240836, content=学习好资料！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Tue Dec 21 08:51:55 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=995605, encodeId=fa51995605c5, content=也想看看，学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d25474509, createdName=ms1000001533276611, createdTime=Sat Jul 03 08:03:58 CST 2021, time=2021-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976756, encodeId=31999e675695, content=很想看看！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c03d1531849, createdName=429890922, createdTime=Fri Jun 25 10:52:31 CST 2021, time=2021-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974390, encodeId=0dae9e439003, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72da5342867, createdName=ms3000001513748709, createdTime=Thu Jun 17 14:20:00 CST 2021, time=2021-06-17, status=1, ipAttribution=)]
    2021-07-03 ms1000001533276611

    也想看看，学习学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1208587, encodeId=cfc3120858ea2, content=非常好的资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=00ec8098175, createdName=ms3000000771933475, createdTime=Mon Apr 04 18:50:43 CST 2022, time=2022-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082408, encodeId=48bb108240836, content=学习好资料！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Tue Dec 21 08:51:55 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=995605, encodeId=fa51995605c5, content=也想看看，学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d25474509, createdName=ms1000001533276611, createdTime=Sat Jul 03 08:03:58 CST 2021, time=2021-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976756, encodeId=31999e675695, content=很想看看！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c03d1531849, createdName=429890922, createdTime=Fri Jun 25 10:52:31 CST 2021, time=2021-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974390, encodeId=0dae9e439003, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72da5342867, createdName=ms3000001513748709, createdTime=Thu Jun 17 14:20:00 CST 2021, time=2021-06-17, status=1, ipAttribution=)]
    2021-06-25 429890922

    很想看看！

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1208587, encodeId=cfc3120858ea2, content=非常好的资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=00ec8098175, createdName=ms3000000771933475, createdTime=Mon Apr 04 18:50:43 CST 2022, time=2022-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082408, encodeId=48bb108240836, content=学习好资料！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Tue Dec 21 08:51:55 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=995605, encodeId=fa51995605c5, content=也想看看，学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32d25474509, createdName=ms1000001533276611, createdTime=Sat Jul 03 08:03:58 CST 2021, time=2021-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976756, encodeId=31999e675695, content=很想看看！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c03d1531849, createdName=429890922, createdTime=Fri Jun 25 10:52:31 CST 2021, time=2021-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974390, encodeId=0dae9e439003, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72da5342867, createdName=ms3000001513748709, createdTime=Thu Jun 17 14:20:00 CST 2021, time=2021-06-17, status=1, ipAttribution=)]
    2021-06-17 ms3000001513748709

    谢谢分享

    0

以上为热门评论，梅斯医学App还有更多内容

相关指南

二代测序技术在NSCLC中的临床应用中国专家共识（2020版）

中国临床肿瘤学会(CSCO,Chinese Society of Clinical Oncology) · 2020-09-20

早期非小细胞肺癌立体定向放疗中国专家共识（2019版）

中华医学会放射肿瘤学会 · 2020-07-30

2020 CCO加拿大共识：晚期EGFR突变非小细胞肺癌的系统治疗流程

加拿大安大略癌症治疗中心(CCO,Cancer Care Ontario) · 2020-04-27

2020 ATORG专家共识声明：优化Ⅲ期非小细胞肺癌的管理

国外肿瘤科相关专家小组（统称） · 2020-03-15

拓展阅读

ASCO指南：IV期非小细胞肺癌的维持治疗（2009）

美国临床肿瘤学会(ASCO,American Society of Clinical Oncology) · 2009-12-20

2010CCO 晚期非小细胞肺癌一线全身化疗

加拿大安大略癌症治疗中心(CCO,Cancer Care Ontario) · 2010-01-01

2011 中国非小细胞肺癌患者表皮生长因子受体基因突变检测专家共识

中华医学会病理学分会 · 2010-01-01

2010ESMO临床实践指南：早期和局部晚期（非转移性）非小细胞肺癌

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2010-03-01

2010ESMO临床实践指南：转移性非小细胞肺癌的诊断、治疗和随访

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2010-03-01

ASCO临时临床意见：考虑一线使用EGFR-TKI(表皮生长因子受体酪氨酸激酶抑制剂)的晚期非小细胞肺癌病人进行EGFR突变检测

美国临床肿瘤学会(ASCO,American Society of Clinical Oncology) · 2011-04-11